Health care stocks were softer Wednesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each declining about 0.2%.
The iShares Biotechnology ETF (IBB) eased 0.1%.
In corporate news, CVS Health (CVS) reported better-than-expected Q4 results and projected higher 2025 earnings. The shares jumped about 16%.
Biogen (BIIB) guided for a decline in earnings and revenue for 2025 amid ongoing challenges in its multiple sclerosis product category, despite reporting stronger-than-expected Q4 results. Its shares fell 5.7%.
NKGen Biotech (NKGN) shares jumped 37% after it said the US Food and Drug Administration granted fast-track designation to troculeucel to treat moderate Alzheimer's disease.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。